2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1196

Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial

Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions

9:00AM-11:00AM: Abstract Number: 1532

Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through 1 Year

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1755

Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis

Vasculitis Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1487

Salivary Gland Ultrasonography (SGUS) and Subclinical Parotid Involvement: Usefulness of Sgus in the Identification of a Subset of Patients with Sjögren’s Syndrome at Higher Risk for Extraglandular Disease Manifestations

Sjögren's Syndrome Poster II: Clinical Research

9:00AM-11:00AM: Abstract Number: 1231

Scope and Consistency of Adherence Related Outcomes in Randomized Controlled Trials of Interventions for Improving Medication Adherence

Patient Outcomes, Preferences, and Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1086

Screening and Intervention of Depression in Rheumatoid Arthritis and Systemic Lupus Erythematosus

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1651

Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1529

Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1523

Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1528

Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels and Correlated with Improvement in Fatigue

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1346

Selective Effect of Rituximab on IgG4 Anti-CCP Autoantibodies in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1743

Serine Arginine/Rich Splicing Factor 1 (SRSF1) Increases IL-2 Production in T Cells By Increasing the Expression of NFAT and c-Fos

T Cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1664

Serum FAS, Ferritin, Igfbp2, sTNFR2 As Markers for Tracking Mucocutaneous and Musculoskeletal Flares in SLE Patients

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1380

Serum Galectin-3 in Rheumatoid Arthritis Compared with Healthy Controls and Subjects with Prediabetes before and after High-Intensity Interval Training

Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

9:00AM-11:00AM: Abstract Number: 1181

Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].